AACR 2026: A Deep Dive into Cancer’s Next Frontier – Key Abstracts & Insights

The American Association for Cancer Research (AACR) is the world’s oldest and largest professional association related to cancer research. The AACR Annual Meeting 2026 is one of the most prominent global oncology conferences, showcasing cutting-edge advances across cancer biology, translational research, and early clinical development. It serves as a key platform for unveiling early-stage (preclinical to Phase II) data, novel mechanisms, and biomarker-driven therapies, often shaping future oncology pipelines and partnerships.

When & Where: April 17–22, 2026 | San Diego, USA

Theme: Precision; Partnership; Purpose; Advancing Cancer Science to Save Lives Globally.

Quick Highlights of AACR 2026

The AACR Annual Meeting 2026 reinforced its position as a leading platform for showcasing early-stage oncology innovation, translational science, and next-generation therapeutic strategies across tumor biology, precision medicine, and clinical development. The strongest attention was directed toward next-generation KRAS/RAS (ON) inhibitors, ADCs, T-cell engagers, CAR-T, and gene therapies, with important readouts across solid tumors and hematologic malignancies, particularly in NSCLC, ovarian cancer, breast cancer, colorectal cancer, and myeloma.

Lung cancer (especially KRAS-driven NSCLC) remained the dominant indication, followed by breast cancer, ovarian cancer, and AML, reflecting areas of high unmet need and commercial opportunity.

Several companies stood out at the meeting, including Greenwich Life Sciences, BriaCell, Calidi, Revolution Medicines, D3 Bio, SELLAS Life Sciences, CStone, Whitehawk Therapeutics, Antengene, HUTCHMED, IDEAYA, Jazz Pharmaceuticals, Genprex, and OBI Pharma. Their programs spanned recurrence-prevention immunotherapy, late-line breast cancer immunotherapy, tumor-localized virotherapy, next-wave ADCs and T-cell engagers, lung cancer gene therapy, and multi-platform biologics, highlighting the breadth and strategic relevance of the AACR 2026 pipeline.

Strategic Takeaways for Industry Leaders

AACR 2026 signals that KRAS-targeted therapy is transitioning into a long-term franchise opportunity, similar to EGFR or HER2, with multiple lines of therapy and lifecycle expansion potential. AACR 2026 highlights a clear paradigm shift in oncology innovation:

• KRAS/RAS biology is now commercially actionable 
• ADCs and cell therapies are evolving into multi-platform ecosystems 
• Precision diagnostics are becoming integral to drug development 
• Early-stage data is increasingly predictive of regulatory acceleration 
• Following Phase I AACR 2026 data, the lunresertib + zedoresertib combination received FDA Fast Track designation for genomically defined platinum-resistant ovarian cancer, supporting accelerated development in a high unmet-need setting

For Pharma stakeholders, investment focus should align with:

• First-in-class biology (KRAS G12D, pan-RAS) 
• Platform scalability (ADCs, cell therapy) 

Novel Therapy Classes with preclinical and Early-Stage Data

AACR 2026 spotlighted a strong shift toward first-in-class and next-generation modalities, with a clear concentration in early-stage (preclinical and Phase I) development. Among these, KRAS-targeted therapies emerged as one of the most prominent and closely watched areas. Early-stage (preclinical/Phase I) abstracts are captured below in the table.

“Following Phase I data presentation at AACR 2026 (MYTHIC trial), Debiopharm received FDA Fast Track designation for the combination of lunresertib (PKMYT1 inhibitor) and zedoresertib (WEE1 inhibitor). The designation targets genomically defined, platinum-resistant ovarian cancer (e.g., CCNE1 amplification, FBXW7/PPP2R1A mutations). The Fast Track status aims to accelerate development and regulatory review, reflecting strong potential in a high unmet-need setting.”

D3 Bio’s multi-layered strategy targeting both validated (G12C) and emerging (G12D, MAPK) pathways

D3 Bio highlighted a KRAS-focused pipeline across major solid tumors, led by Elisrasib (D3S-001), a next-generation KRAS G12C inhibitor in NSCLC, CRC, and PDAC. Clinical data show deeper and more durable responses, including in patients resistant to earlier therapies, underscoring its potential to improve outcomes in KRAS G12C–mutant NSCLC. Currently, sotorasib (LUMAKRAS) and adagrasib (KRAZATI) are approved for this population.

CStone’s pipeline advancement into next-generation ADCs

The Company presented promising preclinical data for three of its novel or differentiated antibodies. If translated into clinical success, these assets could substantially increase CStone’s addressable market and revenue potential, making this news potentially price-sensitive and impactful for share value. ADCs, CS5007 (EGFR/HER3), CS5006 (ITGB4), and CS5008 (DLL3/SSTR2).

Antengene Highlighting Next-Generation ADC and AnTenGager T-cell engager (TCE)

Antengene demonstrated strong momentum in the bispecific and TCE space with ATG-125, ATG-106, and ATG-112. Leveraging its AnTenGager platform, the company aims to mitigate cytokine release syndrome (CRS) while enabling targeting of low-antigen–expressing tumors, including ovarian and renal cancers. These preclinical findings position Antengene at the forefront of expanding TCEs beyond hematologic malignancies into solid tumors, highlighting early-stage yet high-potential immunotherapy assets.

Verismo Therapeutics presented clinical data for its multi-chain KIR-CAR platform (SynKIR-110)

Verismo Therapeutics presented late-breaking Phase I data on KIR-CAR therapy SynKIR-110, demonstrating early clinical activity and strong safety in mesothelin-expressing solid tumors, marking a significant step toward expanding CAR-T therapies beyond hematologic malignancies into solid tumors.

KRAS/RAS(ON) Inhibitors (Next-generation targeted therapy):

The KRAS/RAS pathway emerged as one of the most strategically important themes at AACR 2026, reflecting a transition from “undruggable” biology to a highly competitive and differentiated therapeutic landscape.

Zoldonrasib (RMC-9805): Revolution Medicines presented Phase I data of oral RAS (ON) G12D-selective inhibitor in patients with previously treated KRAS NSCLC. Early Phase I data showed encouraging anti-tumor activity in NSCLC. The emerging profile supports advancing zoldonrasib across monotherapy and combination settings in lung cancer and other RAS G12D-driven cancers.

Daraxonrasib: Revolution Medicines is riding high on pivotal data with its pan-RAS inhibitor daraxonrasib, but its KRAS G12D-selective inhibitor zoldonrasib also continues to look good. Revolution Medicines Moves beyond mutation-specific targeting. Potential to become a backbone therapy across multiple cancers. Revolution Medicines’ Daraxonrasib Nearly Doubles Survival in KRAS-Mutant Pancreatic Cancer.

BlossomHill Therapeutics presented new preclinical data supporting the continued advancement of its clinical programs, BH-30643, a first-in-class, mutant-selective, macrocyclic OMNI-EGFRTM inhibitor, and BH-30236, an oral CLK inhibitor for hematologic malignancies. BH-501284, a non-covalent, pan-KRAS inhibitor for the treatment of diverse KRAS-mutant tumors.

Oncology Expert Perspectives and Insights

Experts from across oncology specialties highlight research being presented at the 2026 AACR Annual Meeting.

• The researchers focused on the RNA-modifying enzyme NAT10 and its interaction with the oncogene MYC. They found that elevated NAT10 activity promoted immune evasion by enhancing autophagy-mediated loss of MHC class I molecules, which are essential for immune cells to recognize and target cancer.
• The researchers say the AI model is especially useful in situations where data are scarce, such as rare patient immune types or newly identified cancer targets. The approach could help speed the development of personalized cancer vaccines and immune-based treatments.
• One of the biggest challenges in immunotherapy is determining which peptides are actually presented by MHC molecules and can be recognized by T cells. By combining AlphaFold 3 structural predictions with a geometry-aware learning framework, our approach captures the physical interactions underlying peptide–MHC binding, allowing us to identify promising epitopes with higher accuracy even in low-data settings.
• Researchers discovered a metabolic vulnerability in Acute Myeloid Leukemia (AML). Leukemia cells depend on the protein eIF4A1 to generate the nutrients they need for rapid growth. By blocking this protein in preclinical models, scientists were able to disrupt the cancer’s energy supply, slowing disease progression and extending survival when combined with other metabolic-targeted drugs.